Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Clinton: Genomics patents OK

President Clinton today acknowledged his role in crashing genomics stocks in March, and said that private companies should be able to patent their genomics discoveries with specific commercial applications.

Genomics stocks responded strongly, with Celera (CRA) up $41.375 (56 percent) to $115 (nearly

Read the full 437 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers